LATAH COUNTY CANCER PROFILE

A publication from the Cancer Data Registry of Idaho, Idaho Hospital Association.

Cancer Incidence 2017–2021 Cancer Mortality 2018–2022 BRFSS 2011–2022

RISK FACTORS AND INTERVENTIONS

CANCER

Cancer is a group of over 100 different diseases, each characterized by the uncontrolled growth and spread of abnormal cells. Cancer risk increases with age and varies by gender and race. As the average age of the population increases, the incidence of cancer will increase as well.

An estimated 42% of all cancers in the United States are due to personal lifestyle factors, such as smoking and sedentary lifestyle, and are preventable (10.3322/caac.21440). Cancers are also attributable to environmental factors and geneenvironment interactions. Other non-modifiable factors, such as age, sex, and family history of specific cancers, are also associated with cancer risk and can help identify people at elevated risk for developing cancer.

For some cancers, early detection can save lives. For example, colorectal cancer screening reduces mortality in adults aged 50–75 years (10.1001/jama.2017.3332). Improved primary prevention, early detection, and effective treatment can reduce the burden of cancer in Idaho.

Aging:

As the population ages, the number of new cancer cases and cancer deaths that occur each year will continue to increase. This trend could be reversed through significant improvements in primary prevention, early detection, and treatment.

Smoking:

Smoking and the use of smokeless tobacco are responsible for most cancers of the lung, trachea, bronchus, larynx, pharynx, oral cavity, and esophagus. Smoking is the leading cause of preventable death in the United States (PMID: 24455788).

Diet:

The U.S. Departments of Agriculture and Health and Human Services recommend the following dietary guidelines: eat a variety of foods; choose a diet with plenty of fruits, vegetables, and whole-grain products; limit the use of sugar, salt, and solid fats; and minimize alcoholic beverage consumption. For details, see https://www.dietaryguidelines.gov

Screening:

Early detection through screening reduces morbidity and mortality for cancers that can be diagnosed early and treated.

FOR MORE INFORMATION

Cancer Data Registry of Idaho P.O. Box 1278 Boise, ID 83701 208-489-1380 https://www.idcancer.org National Cancer Institute
Cancer Information Services
1-800-4CANCER
https://www.cancer.gov/contact

American Cancer Society https://www.cancer.org

CANCER INCIDENCE 2017–2021

Nearly one in two Idahoans are estimated to develop cancer during their lifetime. During 2017–2021, 47,333 cases of invasive cancer were diagnosed among Idaho residents, and 855 cases of invasive cancer were diagnosed among Latah County residents (Table 1).

Table 1: Incidence of All Cancers, Female Breast, Prostate, Lung and Bronchus, and Colorectal Cancers in Latah County and the State of Idaho, 2017–2021

Cancer Incidence 2017–2021	Latah County	State of Idaho			
All Sites/Types	855	47,333			
Female Breast	133	6,943			
Prostate	153	6,766			
Lung & Bronchus	93	4,959			
Colorectal	48	3,632			

Table 3 (Cancer Incidence 2017–2021, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed cases, person-years, crude rates, age- and sex-adjusted rates, expected number of cases based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected cases in Latah County. The table also shows the number of observed cases, person-

years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all cancers combined, 23 invasive cancer types, in situ breast cancer, non-malignant brain and other central nervous system tumors, and pediatric (0–19 years) cancer. Separate comparisons for males, females, and both sexes combined are included.

As shown in Table 3, the crude incidence rate of invasive cancer in Latah County was 424.3 cases per 100,000 person-years per year during 2017–2021. Comparing this crude rate with the crude rate for the remainder of Idaho (528.7) gives an estimate of the relative burden of disease in Latah County.

The age- and sex-adjusted incidence rate of invasive cancer in Latah County, all sites combined, was 491.6 cases per 100,000 persons per year during 2017–2021. There were statistically significantly fewer cases of cancer in Latah County (855) than expected (919.5) based upon rates in the remainder of the state (p=.033).

There are many reasons why cancer incidence rates differ by county, such as the prevalence of smoking and other lifestyle factors, and access to healthcare.

CANCER MORTALITY 2018–2022

During 2018–2022, cancer was the second leading cause of death in Idaho; 15,233 Idaho residents and 285 Latah County residents died from cancer during this period. Most cancer deaths are from five primary sites: lung, colon, pancreas, female breast, and prostate (Table 2).

Table 2: Overall and Cancer Mortality in Latah County and the State of Idaho, 2018–2022

Mortality 2018–2022	Latah County	State of Idaho			
All Deaths	1,273	80,538			
Cancer Deaths	285	15,233			
% of All Deaths	22.4%	18.9%			
Lung & Bronchus	47	2,937			
Colorectal	18	1,332			
Pancreas	26	1,190			
Female Breast	22	1,111			
Prostate	20	997			

Table 4 (Cancer Mortality 2018–2022, Comparison between Latah County and the Remainder of the State of Idaho) shows the number of observed deaths, person-years, crude rates, age- and sex-adjusted rates, expected number of deaths based upon age- and sex-specific rates in the remainder of Idaho, and p-values for tests comparing the number of observed and expected deaths for Latah County. The table also shows the number of observed deaths, person-years, and crude rates for the remainder of the state of Idaho. Comparisons between the county and the remainder of the state were made for all deaths, all cancer deaths, and 21 specific cancer types. Separate comparisons for males, females, and both sexes combined are included.

The age- and sex-adjusted cancer mortality rate for Latah County, all sites combined, was 161.0 deaths per 100,000 persons per year during 2018–2022, compared with 165.9 for the remainder of the state. There were fewer cancer deaths in Latah County (285) than expected (293.7) based upon rates in the remainder of the state, but the difference was not statistically significant.

Statistical Note: Rates and percentages based upon 12 or fewer cases or deaths (numerator) should be interpreted with caution. Data Note: Mortality data may differ slightly from published official statistics from the Bureau of Vital Records and Health Statistics.

TABLE 3: CANCER INCIDENCE 2017–2021 COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

Site/Type			Latah County					Remainder of Idaho			
All Sites Combined Male 462 102,780 491,6 919,5 0.033	Cancer		Observed	Person	Crude	A.A.I.	Expected		Observed	Person	Crude
All Sites Combined	Site/Type	Sex	Cases		Rate (1)	Rate (1,2)	Cases (3)	P-Value (4)	Cases		Rate (1)
All Sites Combined Female 393 98,718 398.1 457.3 425.1 0.123 21,670 4,381.115 4											528.7
Bladder											562.6 494.6
Bladder											24.8
Brain - malignant											39.6
Brain - malignant Male 11 102,780 10,7 12,0 7,7 0,312 371 4,409,493 Brain - malignant Female 6 98,718 61 6,7 5,5 0,942 269 4,381,115 10,000 2,000 3,000			_								10.0 7.3
Brain - malignant Female 6 98.718 6.1 6.7 5.5 0.942 269 4,381,115 Brain and other CNS - non-malignant Total 33 201,498 16.4 18.8 30.2 0.659 1.514 8,790,608 Brain and other CNS - non-malignant Female 9 102,780 8.8 10.1 9.9 0.931 4.91 4,409,493 Brain and other CNS - non-malignant Female 24 98.718 24.3 27.8 20.2 0.446 1,023 4,381,115 Breast Total 33 201,498 66.0 77.9 133.5 1.000 6.875 8,790,608 Breast Female 133 98.718 134.7 158.0 130.8 0.871 6.810 4.381,115 Breast Female 133 98.718 134.7 158.0 130.8 0.871 6.810 4.381,115 Breast - in situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 Breast - in situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 Breast - in situ Female 36 96,718 36.5 43.2 25.3 0.051 1,329 4,381,115 Breast - in situ Female 36 96,718 36.5 43.2 25.3 0.051 1,329 4,381,115 Breast - in situ Female 26 98,718 23.8 27.7 70.6 0.006 << 3.584 8,790,608 Breast - in situ Female 28 102,780 27.2 32.1 38.5 0.097 1,949 4,409,493 Breast - in situ Female 29 98,718 20.3 23.2 32.1 0.030 << 1.635 4,381,115 Colorectal Male 28 102,780 27.2 32.1 38.5 0.097 1,949 4,409,493 Colorectal Female 20 98,718 20.3 23.2 32.1 0.030 << 1.635 4,381,115 Esophagus Total 14 201,498 6.9 8.1 9.6 0.221 493 8,790,608 Esophagus Total 14 201,498 6.9 8.1 9.6 0.221 493 8,790,608 Esophagus Male 1 102,780 1.7 13.8 8.2 0.60 7.9 13.3 8,790,608 Esophagus Female 2 98,718 2.0 2.3 1.5 0.869 76 4,381,115 Esophagus Female 2 98,718 2.0 2.3 1.5 0.869 76 4,381,115 Esophagus Female 2 98,718 2.0 2.3 1.5 0.869 76 4,381,115 Esophagus Female 3 98,718 3.0 0.0 9 3.3 0.324 1.0											8.4
Brain and other CNS - non-malignant Pemale 9 102,780 8.8 10.1 9.9 0.931 491 4,499,493 Brain and other CNS - non-malignant Pemale 24 98,718 24.3 27.8 20.2 0.446 1,023 4,381,115 Breast Male - 102,780 - - 1.3 0.553 65 4,409,493 Breast Female 133 98,718 134.7 758.0 130.8 0.671 6,810 √361,181 131.8 0.671 6,810 √361,181 131.8 1000 65 4,409,493 8,709,608 8,701 133.7 1000 133.8 790,608 134.7 158.0 130.8 0.671 6,810 √361,181 136.5 130.8 0.671 6,810 √361,181 36.5 130.8 0.671 6,810 √361,115 1000 1000 1000 1000 44,09,493 38.7 1000 0.006 √3,584 8,790,608 1000 7000 7000 7000 7000 <t< td=""><td>Brain - malignant</td><td></td><td></td><td></td><td>6.1</td><td></td><td></td><td></td><td></td><td>4,381,115</td><td>6.1</td></t<>	Brain - malignant				6.1					4,381,115	6.1
Brain and other CNS - non-malignant Female Preast 24 98,718 24.3 27.8 20.2 0.446 1,023 4,381,115 Breast Preast Male -3 102,780 66.0 77.9 133.5 1,000 6,875 8,790,608 Breast Penale 133 201,498 166.0 77.9 133.5 1,000 6,875 8,790,608 Breast In Situ Total 37 201,498 18.4 21.9 25.6 0,040 > 1,332 8,790,608 Breast In Situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 Breast In Situ Female 36 98,718 36.5 43.2 25.3 0.051 1.329 4,381,115 Cervix Female 5 98,718 5.1 5.8 5.7 0.991 288 4,381,115 Colorectal Male 28 102,498 23.8 22.7 7.06 0.006 3,584 8,790,608											17.2
Breast Breast Total 133 breast 201,498 breast 66.0 77.9 133.5 1,000 breast 6,875 breast 8,790,608 breast Breast Female 133 98,718 breast 134,7 breast 158.0 130.8 breast 0.655 dreast 4,009,493 breast 1,000 breast <t< td=""><td>Brain and other CNS - non-malignant</td><td></td><td>_</td><td>98 718</td><td></td><td></td><td></td><td></td><td></td><td></td><td>11.1 23.4</td></t<>	Brain and other CNS - non-malignant		_	98 718							11.1 23.4
Breast Female 133 98,718 134.7 158.0 130.8 0.871 6,810 4,331,115 1 Breast - in situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 8,718 36.5 43.2 25.3 0.051 1,329 4,381,115 5 6,004 25.3 0.051 1,329 4,381,115 5 6,70 991 289 4,381,115 5 6,70 991 289 4,381,115 5 6,70 991 289 4,381,115 5 6,70 991 289 4,381,115 6 0006 <											78.2
Breast - in situ Total 37 201,498 18.4 21.9 25.6 0.040 ≫ 1.332 8,790,608 Breast - in situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 Breast - in situ Female 36 98,718 36.5 43.2 25.3 0.051 1,329 4,381,115 Cervix Female 5 98,718 5.1 5.8 5.7 0.991 288 4,381,115 Colorectal Male 28 102,780 27.2 32.1 38.5 0.097 1,949 4,409,493 Colorectal Female 20 98,718 20.3 32.1 38.5 0.097 1,949 4,409,493 Colorectal Female 20 98,718 20.3 32.6 25.6 1.000 1,329 4,381,115 Corpus Uteri Female 25 98,718 25.3 29.6 25.6 1.000 1,329 4,381,115			-		-	-					1.5
Breast - in situ Male 1 102,780 1.0 1.2 0.1 0.112 3 4,409,493 4,381,115 Cervix Female 5 98,718 5.1 5.8 5.7 0.991 289 4,381,115 Colorectal Total 48 201,498 23.8 27.7 70.6 0.006 <<											155.4 15.2
Breast - in situ			1								0.1
Colorectal					36.5	43.2		0.051			30.3
Colorectal Male 28 102,780 27.2 32.1 38.5 0.097 1.949 4,409,493 Colorectal Female 20 98,718 20.3 23.2 32.1 0.030 << 1,635 4,381,115 Corpus Uteri Female 25 98,718 25.3 29.6 25.6 1.000 1,329 4,381,115 Esophagus Total 14 201,498 6.9 8.1 9.6 0.221 493 8,790,608 Esophagus Female 2 102,780 11.7 13.8 8.2 0.260 417 4,409,493 Esophagus Female 2 201,498 10.0 0.9 5.8 0.388 220 8,790,608 Esophagus Female 2 201,498 1.0 0.9 5.8 0.338 220 8,790,608 Esophagus Female 1 102,780 1.0 0.9 5.8 0.338 220 8,790,608 Esophagus Female 1 102,780 1.0 0.9 3.3 0.324 128 4,409,493 Esophagus Female 1 98,718 1.0 0.8 2.6 0.542 92 4,381,115 Esophagus Female 1 98,718 1.0 0.8 2.6 0.542 92 4,381,115 Esophagus Esophagus Female 1 98,718 1.0 0.8 2.6 0.542 92 4,381,115 Esophagus Esophagus Female 1 98,718 1.0 0.8 2.6 0.542 92 4,381,115 Esophagus Esophagus Female 1 98,718 1.0 0.8 2.6 0.542 92 4,381,115 Esophagus Female 2 102,780 21.4 25.4 25.3 0.590 1,288 4,409,493 Esophagus Esophagus											6.6
Colorectal Female 20 98,718 20.3 23.2 32.1 0.030 << 1,635 4,381,115											40.8 44.2
Corpus Uteri											37.3
Esophagus		Female	25	98,718	25.3	29.6	25.6	1.000	1,329	4,381,115	30.3
Esophagus											5.6
Hodgkin Lymphoma											9.5 1.7
Hodgkin Lymphoma											2.5
Kidney and Renal Pelvis Total 30 201,498 14.9 17.5 37.4 0.255 1,921 8,790,608 Kidney and Renal Pelvis Male 22 102,780 21.4 25.4 25.3 0.590 1,288 4,409,493 Kidney and Renal Pelvis Female 8 98,718 8.1 9.5 12.2 0.281 633 4,381,115 Larynx Total 2 201,498 1.0 1.2 4.3 0.398 218 8,790,608 Larynx Male 1 102,780 1.0 1.2 4.3 0.398 218 8,790,608 Larynx Female 1 98,718 1.0 1.1 1.0 1.000 52 4,381,115 Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Female 14 98,718 10.7 12.5 20.5 0.034 <<											2.9
Kidney and Renal Pelvis Male 22 102,780 21.4 25.4 25.3 0.590 1,288 4,409,493 Kidney and Renal Pelvis Female 8 98,718 8.1 9.5 12.2 0.281 633 4,381,115 Larynx Total 2 201,498 1.0 1.2 4.3 0.398 218 8,790,608 Larynx Male 1 102,780 1.0 1.2 3.3 0.324 166 4,409,493 Larynx Female 1 98,718 1.0 1.1 1.0 1.000 52 4,381,115 Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Male 11 102,780 10.7 12.5 20.5 0.034 <			· ·								2.1
Kidney and Renal Pelvis Female 8 98,718 8.1 9.5 12.2 0.281 633 4,381,115 Larynx Total 2 201,498 1.0 1.2 4.3 0.398 218 8,790,608 Larynx Male 1 102,780 1.0 1.2 3.3 0.324 166 4,409,493 Larynx Female 1 98,718 1.0 1.1 1.0 1.000 52 4,381,115 Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Total 25 201,498 10.7 12.5 20.5 0.034 <											21.9 29.2
Larynx Total 2 201,498 1.0 1.2 4.3 0.398 218 8,790,608 Larynx Male 1 102,780 1.0 1.2 3.3 0.324 166 4,409,493 Larynx Female 1 98,718 1.0 1.1 1.0 1.000 52 4,381,115 Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Male 11 102,780 10.7 12.5 20.5 0.034 1,025 4,409,493 Leukemia Female 14 98,718 14.2 16.1 13.4 0.941 677 4,381,115 Liver and Bile Duct Total 12 201,498 6.0 7.0 16.3 0.351 831 8,790,608 Liver and Bile Duct Male 11 102,780 10.7 12.6 11.5 1.000 583 4,409,493 Liver and Bile Duct </td <td></td> <td></td> <td></td> <td>98 718</td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>14.4</td>				98 718							14.4
Larýnx Female 1 98,718 1.0 1.1 1.0 1.000 52 4,381,115 Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Male 11 102,780 10.7 12.5 20.5 0.034 1,025 4,499,493 Leukemia Female 14 98,718 14.2 16.1 13.4 0.941 677 4,381,115 Liver and Bile Duct Total 12 201,498 6.0 7.0 16.3 0.351 831 8,790,608 Liver and Bile Duct Male 11 102,780 10.7 12.6 11.5 1.000 583 4,409,493 Liver and Bile Duct Female 1 98,718 1.0 1.2 4.8 0.092 248 4,381,115 Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608											2.5
Leukemia Total 25 201,498 12.4 14.3 33.8 0.144 1,702 8,790,608 Leukemia Male 11 102,780 10.7 12.5 20.5 0.034 <											3.8
Leukemia Male 11 102,780 10.7 12.5 20.5 0.034 < 1,025 4,409,493 Leukemia Female 14 98,718 14.2 16.1 13.4 0.941 677 4,381,115 Liver and Bile Duct Total 12 201,498 6.0 7.0 16.3 0.351 831 8,790,608 Liver and Bile Duct Male 11 102,780 10.7 12.6 11.5 1.000 583 4,409,493 Liver and Bile Duct Female 1 98,718 1.0 1.2 4.8 0.092 248 4,381,115 Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608 Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.846 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,11											1.2 19.4
Leukemia Female 14 99,718 14.2 16.1 13.4 0.941 677 4,381,115 Liver and Bile Duct Total 12 201,498 6.0 7.0 16.3 0.351 831 8,790,608 Liver and Bile Duct Male 11 102,780 10.7 12.6 11.5 1.000 583 4,409,493 Liver and Bile Duct Female 1 98,718 1.0 1.2 4.8 0.092 248 4,381,115 Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608 Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.464 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,115 Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 <											23.2
Liver and Bile Duct Male 11 102,780 10.7 12.6 11.5 1.000 583 4,409,493 Liver and Bile Duct Female 1 98,718 1.0 1.2 4.8 0.092 248 4,381,115 Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608 Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.464 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,115 Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 <											15.5
Liver and Bile Duct Female 1 98,718 1.0 1.2 4.8 0.092 248 4,381,115 Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608 Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.464 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,115 Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 <											9.5
Lung and Bronchus Total 93 201,498 46.2 54.0 95.3 0.870 4,866 8,790,608 Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.464 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,115 Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 <											13.2 5.7
Lung and Bronchus Male 43 102,780 41.8 49.1 48.7 0.464 2,452 4,409,493 Lung and Bronchus Female 50 98,718 50.6 59.1 46.6 0.661 2,414 4,381,115 Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 <											55.4
Melanoma of the Skin Total 46 201,498 22.8 26.3 61.7 0.045 < 3,098 8,790,608 Melanoma of the Skin Male 25 102,780 24.3 28.4 37.4 0.042 <											55.6
Melanoma of the Skin Male 25 102,780 24.3 28.4 37.4 0.042 << 1,870 4,409,493											55.1
											35.2
	Melanoma of the Skin	Female		98,718	24.3	24.1	24.5	0.042	1,870	4,381,115	42.4 28.0
Myeloma Total 13 201,498 6.5 7.6 14.0 0.937 715 8,790,608	Myeloma			201,498						8,790,608	8.1
Myeloma Male 10 102,780 9.7 11.5 8.6 0.723 437 4,409,493	Myeloma			102,780						4,409,493	9.9
Myeloma Female 3 98,718 3.0 3.5 5.4 0.435 278 4,381,115											6.3
Non-Hodgkin Lymphoma Total 40 201,498 19.9 22.7 39.1 0.931 1,952 8,790,608 Non-Hodgkin Lymphoma Male 25 102,780 24.3 28.0 22.7 0.685 1,121 4,409,493											22.2 25.4
Non-Hodgkin Lymphoma Female 15 98,718 15.2 17.2 16.5 0.832 831 4,381,115	lon-Hodgkin Lymphoma	Female	15	98,718	15.2		16.5	0.832	831	4,381,115	19.0
Oral Cavity and Pharynx Total 29 201,498 14.4 16.9 25.1 0.487 1,286 8,790,608				201,498	14.4			0.487	1,286	8,790,608	14.6
Oral Cavity and Pharynx Male 24 102,780 23.4 27.7 18.0 0.201 916 4,409,493 Oral Cavity and Pharynx Female 5 98,718 5.1 5.9 7.2 0.549 370 4,381,115											20.8 8.4
Ovary Female 7 98,718 7.1 8.1 10.8 0.310 546 4,381,115	, ,										12.5
Pancreas Total 29 201,498 14.4 16.8 28.7 1.000 1,459 8,790,608											16.6
Pancreas Male 13 102,780 12.6 14.8 16.1 0.526 813 4,409,493											18.4
Pancreas Female 16 98,718 16.2 18.7 12.6 0.409 646 4,381,115 Prostate Male 153 102,780 148.9 175.3 130.9 0.063 6,613 4,409,493 1											14.7 150.0
Prostate Male 153 102,780 148.9 175.3 130.9 0.063 6,613 4,409,493 1 Stomach Total 7 201,498 3.5 4.0 9.2 0.601 467 8,790,608											5.3
Stomach Male 6 102,780 5.8 6.9 5.9 1.000 301 4,409,493							5.9	1.000		4,409,493	6.8
Stomach Female 1 98,718 1.0 1.2 3.3 0.321 166 4,381,115										4,381,115	3.8
Testis Male 4 102,780 3.9 3.4 7.2 0.306 270 4,409,493											6.1
Thyroid Total 19 201,498 9.4 9.9 25.5 0.230 1,166 8,790,608	•										13.3
Thyroid Male 4 102,780 3.9 4.4 7.5 0.258 368 4,409,493 Thyroid Female 15 98,718 15.2 15.4 17.7 0.618 798 4,381,115	•										8.3 18.2
Pediatric Age 0 to 19 Total 5 49,735 10.1 9.6 8.9 0.240 420 2,449,589											17.1
Pediatric Age 0 to 19 Male 4 25,061 16.0 15.8 4.3 1.000 210 1,249,260											16.8
Pediatric Age 0 to 19 Female 1 24,674 4.1 3.8 4.7 0.107 210 1,200,329			1								17.5

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

^{2.} Age and sex-adjusted incidence (A.A.I.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

[&]quot;<<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

TABLE 4: CANCER MORTALITY 2018–2022 COMPARISON BETWEEN LATAH COUNTY AND THE REMAINDER OF THE STATE OF IDAHO

		Latah County						Remainder of Idaho			
Cause of Death		Observed	Person	Crude	A.A.M.	Expected		Observed	Person	Crude	
Cancer Site/Type	Sex	Deaths	Years	Rate (1)	Rate (1,2)	Deaths (3)	P-Value (4)	Deaths	Years	Rate (1)	
All Causes of Death	Total	1,273	202,573	628.4	693.2	1,615.8	0.000 <<	79,262	9,008,821	879.8	
All Causes of Death	Male	667	103,314	645.6	721.0	861.3	0.000 <<	42,119	4,524,383	930.9	
All Causes of Death	Female	606	99,259	610.5	662.4	757.8	0.000 <<	37,143	4,484,438	828.3	
All Malignant Cancers	Total	285	202,573	140.7	161.0	293.7	0.636	14,948	9,008,821	165.9	
All Malignant Cancers	Male	153 132	103,314 99,259	148.1	170.7 150.9	160.1 133.9	0.607 0.915	8,082 6,866	4,524,383 4,484,438	178.6 153.1	
All Malignant Cancers Bladder	Female Total	9	202,573	133.0 4.4	5.0	9.6	1.000	476	9,008,821	5.3	
Bladder	Male	8	103,314	7.7	8.8	7.4	0.920	367	4,524,383	8.1	
Bladder	Female	1	99,259	1.0	1.1	2.2	0.717	109	4,484,438	2.4	
Brain and Other Nervous System	Total	13	202,573	6.4	7.3	10.0	0.413	505	9,008,821	5.6	
Brain and Other Nervous System	Male	6	103,314	5.8	6.5	5.7	1.000	283	4,524,383	6.3	
Brain and Other Nervous System	Female	7	99,259	7.1	8.1	4.3	0.285	222	4,484,438	5.0	
Breast	Total	22	202,573	10.9	12.4	21.6	0.996	1,102	9,008,821	12.2	
Breast	Male	-	103,314	-	- 05.4	0.3	1.000	13	4,524,383	0.3	
Breast Convix	Female	22	99,259 99,259	22.2	25.1	21.3	0.931 0.357	1,089 88	4,484,438 4,484,438	24.3 2.0	
Cervix Colorectal	Female Total	- 18	202,573	- 8.9	10.2	1.7 25.7	0.357 0.145	1,314	4,484,438 9,008,821	14.6	
Colorectal	Male	8	103,314	7.7	9.1	14.1	0.145	724	4,524,383	16.0	
Colorectal	Female	10	99,259	10.1	11.4	11.6	0.783	590	4,484,438	13.2	
Corpus Uteri	Female	6	99,259	6.0	6.9	3.1	0.197	163	4,484,438	3.6	
Esophagus	Total	14	202,573	6.9	8.0	8.6	0.115	447	9,008,821	5.0	
Esophagus	Male	12	103,314	11.6	13.6	7.4	0.149	379	4,524,383	8.4	
Esophagus	Female	2	99,259	2.0	2.3	1.3	0.753	68	4,484,438	1.5	
Hodgkin Lymphoma	Total	-	202,573	-	-	0.5	1.000	25	9,008,821	0.3	
Hodgkin Lymphoma	Male	-	103,314	-	-	0.3	1.000	14	4,524,383	0.3	
Hodgkin Lymphoma Kidney	Female Total	- 5	99,259 202,573	2.5	2.8	0.2 7.5	1.000 0.483	11 381	4,484,438 9,008,821	0.2 4.2	
Kidney	Male	4	103,314	3.9	4.5	4.8	0.463	242	4,524,383	5.3	
Kidney	Female	1	99,259	1.0	1.1	2.7	0.483	139	4,484,438	3.1	
Larynx	Total		202,573	-	-	1.5	0.460	76	9,008,821	0.8	
Larynx	Male	-	103,314	-	-	1.3	0.557	65	4,524,383	1.4	
Larynx	Female	-	99,259	-	-	0.2	1.000	11	4,484,438	0.2	
Leukemia	Total	16	202,573	7.9	9.0	12.8	0.442	649	9,008,821	7.2	
Leukemia	Male	8	103,314	7.7	8.9	7.8	1.000	389	4,524,383	8.6	
Leukemia	Female	8	99,259	8.1	9.1	5.1	0.290	260	4,484,438	5.8	
Liver and Bile Duct Liver and Bile Duct	Total Male	16 12	202,573 103,314	7.9 11.6	9.2 13.5	12.0 8.1	0.313 0.235	619 411	9,008,821 4,524,383	6.9 9.1	
Liver and Bile Duct	Female	4	99,259	4.0	4.7	4.0	1.000	208	4,484,438	4.6	
Lung and Bronchus	Total	47	202,573	23.2	26.8	56.3	0.235	2,890	9,008,821	32.1	
Lung and Bronchus	Male	23	103,314	22.3	25.8	29.9	0.236	1,518	4,524,383	33.6	
Lung and Bronchus	Female	24	99,259	24.2	27.7	26.5	0.720	1,372	4,484,438	30.6	
Melanoma of the Skin	Total	9	202,573	4.4	5.1	5.7	0.252	292	9,008,821	3.2	
Melanoma of the Skin	Male	4	103,314	3.9	4.5	3.8	1.000	196	4,524,383	4.3	
Melanoma of the Skin	Female	5	99,259	5.0	5.6	1.9	0.089	96	4,484,438	2.1	
Myeloma	Total	4	202,573	2.0	2.3	6.3	0.495	321	9,008,821	3.6	
Myeloma Myeloma	Male Female	1 3	103,314 99,259	1.0 3.0	1.1 3.5	3.7 2.6	0.230 0.956	187 134	4,524,383 4,484,438	4.1 3.0	
Non-Hodgkin Lymphoma	Total	12	202,573	5.9	6.8	11.0	0.936	556	9,008,821	6.2	
Non-Hodgkin Lymphoma	Male	7	103,314	6.8	7.8	6.0	0.634	303	4,524,383	6.7	
Non-Hodgkin Lymphoma	Female	5	99,259	5.0	5.7	5.0	1.000	253	4,484,438	5.6	
Oral Cavity and Pharynx	Total	4	202,573	2.0	2.3	5.3	0.789	271	9,008,821	3.0	
Oral Cavity and Pharynx	Male	4	103,314	3.9	4.5	3.7	1.000	188	4,524,383	4.2	
Oral Cavity and Pharynx	Female	-	99,259		<u> </u>	1.6	0.404	83	4,484,438	1.9	
Ovary	Female	5	99,259	5.0	5.8	6.8	0.641	356	4,484,438	7.9	
Pancreas	Total	26	202,573	12.8	14.8	22.6	0.534	1,164	9,008,821	12.9	
Pancreas Pancreas	Male Female	13 13	103,314 99,259	12.6	14.6 15.0	12.5 10.2	0.963 0.456	637 527	4,524,383 4,484,438	14.1	
Pancreas Prostate	Male	20	99,259 103,314	13.1 19.4	22.0	19.6	0.456	977	4,484,438	11.8 21.6	
Stomach	Total	4	202,573	2.0	22.0	3.7	1.000	190	9,008,821	21.0	
Stomach	Male	3	103,314	2.9	3.4	2.3	0.794	116	4,524,383	2.6	
Stomach	Female	1	99,259	1.0	1.2	1.4	1.000	74	4,484,438	1.7	
			ne number of cases					, ,	., .5 1, 150	1	

Notes: 1. Rates are expressed as the number of cases per 100,000 persons per year (person-years).

Statistical Notes: Rates based upon 12 or fewer cases (numerator) should be interpreted with caution.

Mortality statistics presented differ from BVRHS official statistics due to differences in methodology.

Data Source: Bureau of Vital Records and Health Statistics (BVRHS), Division of Public Health, Idaho Department of Health and Welfare, 2023.

^{2.} Age and sex-adjusted mortality (A.A.M.) rates for county use age and sex-specific crude rates for the remainder of the state as standard.

^{3.} Expected cases are based upon age and sex-specific rates for the remainder of the state of Idaho (compare to observed).

^{4.} P-values compare observed and expected cases, are two tailed, based upon the Poisson probability distribution.

"<" denotes significantly fewer cases observed than expected, ">>" denotes significantly more cases observed than expected (p=.05).

Cancer Screening and Risk Factors

The Division of Public Health (DPH), Idaho Department of Health and Welfare, under a cooperative agreement with the Centers for Disease Control and Prevention, has conducted telephone Behavioral Risk Factor Surveys since 1984. These surveys are conducted with randomly selected adult Idahoans to measure population prevalences of risk factors for major causes of death in the U.S., including cancer. DPH provided Behavioral Risk Factor Surveillance System (BRFSS) data from 2011 through 2022 to CDRI staff, who performed the analyses reported in these *County Profiles*. Analysis weights were post-stratified to 2022 population estimates by age group, sex, and county, beginning with the BRFSS raked weights. Not all questions were asked in all years. Crude prevalence estimates are presented herein; a minimum of 50 respondents was required to generate county-level statistics. Results may differ from IDHW reports due to differences in methods. Cancer screening and risk factor measures were selected to assist in monitoring *Comprehensive Cancer Alliance for Idaho* (CCAI) objectives. Wald log-linear chi-square statistics were used to test for independence of the selected measures and other variables, such as age and race, taking the complex survey design into account.

Cancer Screening and Risk Factor Prevalence Estimates, 2011–2022

	State of								Latah
Measure	Idaho	HD 1	HD 2	HD 3	HD 4	HD 5	HD 6	HD 7	County
Access to Care Have Health Insurance, Age < 65 (2021–2022) Not See Doctor Due to Cost in Past Year (2020–2022)	90.0% 10.4%	89.3% 9.5%	87.8% 11.0%	86.4% 11.0%	92.6% 10.2%	87.2% 10.2%	89.1% 10.4%	92.6% 11.3%	91.9% 9.8%
Cancer Screening									
Mammogram Past 2 Years, Age 40–74 (2014–2022, even years) Pap Test Past 3 Years, Cervix Intact Age 21–65 (2018, 2020) Colorectal Cancer Screening, Age 45–75 (2022) Tobacco Use	62.9% 71.1% 63.3%	61.0% 73.7% 61.0%	70.0% 73.6% 62.5%	60.3% 70.9% 60.8%	66.1% 72.9% 67.2%	58.9% 69.4% 65.0%	61.0% 69.3% 60.4%	62.5% 65.5% 60.2%	70.8% 76.2% 59.5%
Current Tobacco User (2020–2022) Other Cancer-Related	22.1%	24.3%	20.4%	24.8%	21.3%	22.5%	22.6%	18.1%	21.1%
Healthy Weight by Body Mass Index, Age 20+ (2020–2022)	30.0%	30.0%	30.1%	26.5%	33.7%	27.5%	26.7%	30.2%	35.1%
Any Physical Activity Besides Job Past 30 Days (2018–2022)	79.1%	79.0%	78.0%	75.4%	82.7%	75.2%	76.7%	81.0%	85.2%
Meet Physical Activity Guidelines (2011, 2013, 2015, 2017, 2019)	22.0%	22.8%	19.2%	20.0%	25.2%	19.5%	20.4%	20.3%	23.3%
Home Ever Tested for Radon (2016, 2018, 2020)	22.9%	30.8%	18.3%	16.9%	25.2%	20.1%	23.0%	21.0%	21.0%

Access to Care

Have Health Insurance – 2021–2022

Statewide, 90.0% of adults aged 18–64 reported having health care coverage. Health care coverage differed significantly by race/ethnicity, with 91.4% of white non-Hispanics, compared to 81.5% of Hispanics and 90.5% of Native Americans, having health insurance. Spanish-speaking respondents were significantly less likely to be insured (46.0%) than English-speaking respondents (90.5%). Health care coverage differed significantly by age of respondent, with 87.2% of persons aged 18–29, and 93.4% of persons aged 50–64, having health insurance. Health care coverage differed significantly by county, with a range of 64.8% in Idaho County to 95.9% in Shoshone County having health insurance.

Not See Doctor Due to Cost in Past Year – 2020–2022

Statewide, 10.4% of adults aged 18+ reported they needed to see a doctor but could not because of cost sometime in the past 12 months. Inability to see a doctor due to cost differed significantly by race/ethnicity (9.2% of white non-Hispanics, 16.9% of Hispanics, and 15.7% of Native Americans). Inability to see a doctor due to cost differed significantly by annual household income (21.9% for less than \$15,000, 5.8% for greater than \$50,000).

Cancer Screening

Mammogram - 2014-2022, even years

Statewide, 62.9% of women aged 40–74 reported having a mammogram in the past 2 years. Insured women were about twice as likely to have had a mammogram in the past 2 years (66.3% versus 31.2%). Mammography rates differed significantly by county, with a range in screening of 41.6% in Owyhee County to 76.1% in Nez Perce County. In 2022, Idaho ranked 49th among states and the District of Columbia for mammography screening rates among women aged 40+.

Pap Test - 2018, 2020

Statewide, 71.1% of women with an intact cervix and aged 21–65 reported having a Pap test in the past 3 years. Women with health insurance were significantly more likely to have timely Pap screening than uninsured women (75.0% versus 52.8% screened in the past 3 years). Pap screening differed significantly by county, with a range of 50.6% in Bingham County to 78.9% in Bannock County. In 2020, Idaho ranked 49th among states and the District of Columbia for Pap screening rate.

<u>Colorectal Cancer Screening</u> – 2022

Statewide, 63.3% of adults aged 45–75 reported being current for colorectal cancer screening.** Persons with health insurance were over twice as likely to be current for colorectal cancer screening. In 2022, Idaho ranked 42nd among states and the District of Columbia in the percentage of adults aged 45–75 and older who reported being up-to-date for colorectal cancer screening.

^{**} Current for colorectal cancer screening means a blood stool test in the past year, sigmoidoscopy in the past 5 years and blood stool test in the past 3 years, blood stool DNA test in the past 3 years, virtual colonoscopy in the past 5 years, or a colonoscopy in the past 10 years.

Cancer Screening and Risk Factors

Tobacco Use

Current Tobacco Use - 2020-2022

Current tobacco use includes at least 1 form of cigarettes; cigars, cigarillos, filtered little cigars; regular pipes, water pipes, hookah; e-cigarettes; and/or smokeless tobacco products every day or some days. Statewide, 22.1% of adults aged 18 and older were current tobacco users. Tobacco use differed significantly by age of respondent, with 28.9% of persons aged 18–29, and 10.7% of persons aged 65 and older reporting current tobacco use. Tobacco use was lower among white non-Hispanics (21.5%) than among Native Americans (38.0%). Tobacco use differed significantly by county, with a range of 6.1% in Madison County to 33.5% in Elmore County. Counties with higher rates of tobacco use had significantly higher rates of lung cancer.

Other Cancer-Related

Healthy Weight by Body Mass Index - 2020-2022

Statewide, 30.0% of adults aged 20 and older were in the healthy weight range as measured by body mass index (BMI 18.5–24.9). BMI differed significantly by race/ethnicity, with 30.5% of white non-Hispanics, compared to 25.8% of Hispanics and 21.5% of Native Americans, being in the healthy weight range. Males (24.4%) were significantly less likely to be in the healthy weight range than females (35.7%). BMI differed significantly by age of respondent, with 41.1% of persons aged 18–29, and 23.4% of persons aged 50–64, being in the healthy weight range. BMI differed significantly by county, with a range of 11.7% in Power County to 44.3% in Blaine County of adults being in the healthy weight range.

Any Physical Activity - 2018-2022

CCAI is measuring physical activity with two metrics: Any physical activity besides job in past 30 days and meeting aerobic and strength physical activity guidelines during the past month or week. Statewide, 79.1% of adults aged 18 and older reported physical activity besides their job in the past 30 days. Physical activity differed significantly by age of respondent, with 83.7% of persons aged 18–29, and 72.5% of persons aged 65+, reporting any physical activity besides their job. The percentage of adults reporting any physical activity differed significantly by county, with a range of 66.9% in Oneida County to 88.3% in Teton County. Counties with higher rates of physical activity had significantly lower rates of overall and colorectal cancer.

Physical Activity Guidelines – 2011, 2013, 2015, 2017, 2019 Statewide, 22.0% of adults aged 18 and older met aerobic and strength physical activity guidelines during the past month or week. Meeting physical activity guidelines differed significantly by age of respondent, with 26.2% of persons aged 18–29, and 19.2% of persons aged 50–64, meeting guidelines. The percentage of adults meeting physical activity guidelines differed significantly by county, with a range of 9.5% in Franklin County to 30.7% in Blaine County.

Home Radon Testing - 2016, 2018, 2020

Statewide, 22.9% of adults have ever tested their house for radon. Radon test usage varied significantly by race/ethnicity, with 25.1% of white non-Hispanics, 7.3% of Hispanics, and 25.4% of Native Americans having ever tested their house for radon. Radon test usage was higher for persons aged 50+ than for younger persons. Home radon testing differed significantly by county, with a range of 8.7% in Cassia County to 54.7% in Blaine County.

This project has been funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of Health and Human Services, under Contract No. HHSN261201800006I and the Centers for Disease Control and Prevention, Department of Health and Human Services, under Cooperative Agreement NU58DP007160. The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention or the National Cancer Institute.



